General Sense
Alachua, FloridaFounded 2020
Canaery is developing the world’s first nose-computer interface, combining animal olfaction with neurotechnology and artificial intelligence to interpret and prioritize scents. Its technology is intended to enhance working animals for applications ranging from explosives, firearms, narcotics, and pest detection to disease screening.
- Founded
- 2020
- Employees
- 11–50
reccy insights
Canaery’s clearest milestone was its January 6, 2026 seed financing event, although no amount was disclosed for that round. The company’s cumulative funding remains $4 million, with the disclosed amount tied to its July 1, 2022 seed round. That financing included Breakout Ventures as lead investor and was associated with a broader syndicate that included Dolby Family Ventures, KdT Ventures, Asymmetry Ventures, and SOSV-related entities. On March 7, 2024, a Canaery-led research team received support through the U.S. National Science Foundation Convergence Accelerator, indicating progress beyond a standalone product concept and toward applied research. Earlier coverage on June 30, 2022 described the company’s effort to digitize smell through a neural interface, while a July 15, 2021 profile introduced its approach to interpreting animal olfactory signals. The company is now represented publicly as General Sense in parts of its corporate and contact presence, while Canaery remains the product and operating identity in historical materials.
Written by reccy's AI from company sites, press and funding records · updated Oct 2026
What makes General Sense distinct
- 01Developing a novel nose-computer interface that connects animal olfactory systems with computing technology
- 02Combines natural animal scent detection with neurotechnology and artificial intelligence
- 03Targets contraband detection, pest inspections, biosecurity, and disease screening
- 04Founded by specialists in neuroscience, olfaction, machine learning, and neural interfaces
- 05States a commitment to humane animal care and ethical treatment standards
Technology & products
- Nose-Computer Interface (NCI)
A neural implant system that decodes scent information from animals' olfactory signals to identify dangerous compounds.
- Nose-Computer Interface (NCI)
- Neurotechnology for interpreting animal olfactory signals
- Artificial intelligence for scent interpretation and prioritization
- Networked database of detectable odors
About General Sense
- Products
- Nose-Computer Interface (NCI)
- Leadership
- Gabriel Lavella, CEO & Founder
- Focus areas
- AI/ML, neurotechnology, olfaction, scent detection, animal detection, biosecurity, disease detection
- Headquarters
- Alachua, Florida
- Founded
- 2020
- Employees
- 11–50